The study’s authors traced the growing reliance on interventional radiology across two dimensions. On the support side, routine oncologic care increasingly depends on image-guided procedures such as biopsy, venous access, and drainage that fall squarely within the interventional radiology skill set. On the therapeutic side, interventional radiologists now deliver treatments aimed directly at the tumor itself, including percutaneous ablation and transarterial therapies that attack liver tumors from inside the body while sparing healthy tissue. As these roles expanded, the volume of liver cancer patients treated by interventional radiologists rose steadily over the study period.

Primary liver cancer remains one of the world’s deadliest malignancies. It is the third leading cause of cancer-related death globally, with approximately 900,000 new cases reported each year, about 43,000 of them in the United States. Metastatic liver disease compounds the burden, because the liver is a common site of spread for cancers such as colorectal and breast cancer. For this vast patient population, the minimally invasive, image-guided techniques championed by interventional radiology offer an alternative to more aggressive surgical approaches, often with fewer side effects and faster recovery.

At the heart of the specialty’s therapeutic arsenal are transarterial chemoembolization and transarterial radioembolization, procedures that thread catheters through the bloodstream to deliver chemotherapy or radiation directly into the arteries feeding liver tumors, cutting off their blood supply at the same time. Percutaneous thermal and non-thermal ablation techniques, meanwhile, use image guidance to destroy tumor cells in place with heat, cold, or other energy sources. Nishita Kothary, an interventional radiologist and professor at Stanford University School of Medicine who serves as secretary of the Society of Interventional Radiology and co-authored the paper, described these image-guided interventions as capable of being curative, adjunct to systemic therapies, or a bridge to organ transplantation, with fewer side effects than systemic treatments and a faster recovery time that places less strain on a patient’s quality of life.

The economic analysis at the core of the paper reveals a striking asymmetry. Physician payments and patient out-of-pocket costs climbed sharply during the study window, with oncology accounting for the steepest increase at 72 percent over five years. Yet interventional radiology’s overall cost burden to the health care system remained comparatively low. The specialty accounted for just 7.4 percent of total payments while performing 11.7 percent of Work Relative Value Units, a standard Medicare-derived metric that measures the time, skill, and intensity a physician invests in each patient service. By contrast, oncologists accounted for 52.5 percent of total payments while performing 13.7 percent of Work Relative Value Units, and radiation oncologists accounted for 5.4 percent of payments while performing 4.5 percent of those units.

Those figures suggest that interventional radiology delivers a disproportionate share of the work involved in liver cancer care relative to the payments it receives. C. Matthew Hawkins, an interventional radiologist and professor at Emory University School of Medicine who serves as treasurer of the Society of Interventional Radiology and co-authored the study, argued that the specialty provides the same quality of care at a fraction of the cost of oncology, a difference he framed as potentially more valuable to patients, payors, and health care systems when faster recovery times and the frequent absence of hospital stays after interventional radiology treatment are factored in.

The cost-efficiency argument arrives at a moment when the American health care system is under intensifying pressure to rein in spending on cancer care. Hawkins noted that as payors and regulators push for more cost-effective care, the urgency for interventional radiologists to be present at the table in discussions of cancer care policy, cost, and resource allocation only grows. The study’s findings give that argument quantitative teeth: a specialty performing nearly 12 percent of the measured work for under 8 percent of the payments represents exactly the kind of value equation that alternative payment models are designed to reward.

Kothary emphasized that liver cancer demands complex, multidisciplinary care and that interventional radiologists have a central and transformative role to play on the care team. That framing reflects a broader evolution in how the specialty sees itself. Increasingly, interventional radiologists are sub-specializing in oncology, building dedicated practices around tumor ablation, transarterial therapies, and the supportive procedures that keep cancer patients on track with their treatment plans. The result, according to the study, is a care model in which image-guided specialists contribute both the essential infrastructure of modern oncology and increasingly the definitive therapy itself.

Hawkins extended the argument beyond economics, stating that interventional radiology can offer cost-efficient care for hepatobiliary disease with comparable or improved clinical efficacy compared with alternative treatment options offered by other specialties. He insisted that interventional radiologists must be part of the discussion, especially as the system moves toward alternative payment models designed to control the costs of care. For patients, the practical implications are tangible: targeted therapies that can be curative or bridge them to transplantation, delivered through pinhole incisions rather than open surgery, with fewer systemic side effects and recovery measured in days rather than weeks.

As liver cancer incidence continues to climb worldwide and metastatic disease touches hundreds of thousands more patients each year, the study suggests that the trajectory of interventional radiology will keep bending upward. The Medicare data from 2016 to 2021 captured a specialty in ascent, one whose minimally invasive ethos aligns with the simultaneous demands of clinical efficacy, patient quality of life, and system-level cost control. Whether the specialty’s share of payments catches up with its share of work remains an open policy question, but the evidence assembled by the Society of Interventional Radiology-funded team makes a clear case that the future of liver cancer treatment will be increasingly image-guided, increasingly transarterial, and increasingly interventional.

Subject of Research: Interventional Radiology in Liver Cancer Treatment

Article Title: New paper outlines growing role of interventional radiology in liver cancer treatment

Article References: New paper outlines growing role of interventional radiology in liver cancer treatment. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: interventional radiology, liver cancer, hepatobiliary cancer, transarterial chemoembolization, radioembolization, tumor ablation, Medicare data, health care costs, minimally invasive therapy, Society of Interventional Radiology, Journal of Vascular and Interventional Radiology, cancer care policy

The stakes in this debate are anatomical. The thyroid gland is a small, butterfly-shaped structure wrapped around the windpipe, and it shares that crowded space with some of the most delicate structures in the human body. The recurrent laryngeal nerves, which control the vocal cords, run directly alongside the gland; injury to them can leave a patient with permanent hoarseness or breathing difficulties. The parathyroid glands, which regulate calcium, are similarly vulnerable. The trachea, esophagus, and major blood vessels of the neck all lie within millimeters of the thyroid capsule. For these reasons, tumors located adjacent to the capsule, the trachea, or the recurrent laryngeal nerve have traditionally been considered high-risk locations — and many guidelines and practitioners have treated them as contraindications to thermal ablation, reserving heat-based treatment only for tumors comfortably surrounded by normal thyroid tissue.

That conservative stance is now being re-examined. In 2024, an expert consensus broadened the potential indications for thermal ablation in papillary thyroid carcinoma, opening the door to treating tumors that were previously excluded on anatomical grounds. The Zhejiang University team, led by corresponding author Shiyan Li of the Department of Ultrasound, set out to test that expansion empirically. Their question was direct: when a small papillary thyroid carcinoma is classified as being in a high-risk location, does radiofrequency ablation performed by experienced hands produce outcomes that are meaningfully worse than ablation of tumors in low-risk locations? If the answer were no, the anatomical objection to ablation would lose much of its force.

To answer it, the researchers assembled a cohort of 268 patients with T1aN0M0 papillary thyroid carcinoma — the staging designation for tumors one centimeter or smaller with no lymph node involvement and no distant metastasis — who underwent radiofrequency ablation between January 2020 and April 2024. Each tumor was classified according to its position within the gland, dividing the cohort into a high-risk location group and a low-risk location group. All procedures were carried out by senior radiologists with more than five years of ablation experience, a detail the authors emphasize because operator skill is widely believed to be the decisive variable in whether tumors near critical structures can be treated safely. Patients were then followed until September 2025, yielding a median follow-up of 23.5 months.

The technical logic of radiofrequency ablation helps explain both its appeal and its risks. Under ultrasound guidance, a slender electrode is threaded through the skin and into the tumor, and an alternating electrical current is passed through the tissue. The resistance of the tissue generates frictional heat, creating a zone of coagulative necrosis that kills the cancer cells in place. Contrast-enhanced ultrasound is typically used afterward to confirm that the entire tumor has been devascularized. The technique avoids an incision, spares the remaining thyroid tissue, preserves thyroid function in most patients, and can often be performed with local anesthesia and same-day discharge. But near the trachea or the recurrent laryngeal nerve, the same heat that destroys the tumor can theoretically damage those structures, which is precisely why high-risk locations have been treated with such caution.

The primary endpoint of the study was the disease progression rate — whether the cancer grew, spread, or recurred during follow-up. The secondary endpoints covered the practical questions patients care about most: how much the tumor shrank, how often it disappeared completely, and how often complications occurred, along with postoperative anxiety and marked pain. The headline result was striking in its simplicity. Across the entire cohort, the complete tumor disappearance rate was 61.6 percent, and there was no statistically significant difference between the high-risk and low-risk groups, with a p value of 0.665. In other words, tumors nestled against the trachea or the nerve were just as likely to vanish after ablation as tumors in easy-to-treat positions.

Disease progression was rare in both groups, which is itself informative but also creates a statistical challenge. When an outcome is uncommon, conventional regression models can become unstable, so the researchers turned to Firth penalized logistic regression, a method designed to handle rare events and small cell counts. After adjusting for the baseline maximum tumor diameter, they found that high-risk location classification was not significantly associated with disease progression: the adjusted odds ratio was 1.77, with a 95 percent confidence interval stretching from 0.17 to 239.22 and a p value of 0.689. The extraordinarily wide confidence interval is worth pausing on. It reflects the fact that so few patients progressed at all that the data cannot precisely pin down the size of any effect — but the central estimate and the p value both indicate no detectable harm from treating tumors in high-risk positions.

The safety findings followed the same pattern. The researchers detected no significant associations between high-risk tumor location and the incidence of complications, postoperative anxiety, or marked pain. For a field in which fear of nerve injury and tracheal damage has long limited the use of ablation, that null result carries real weight. It suggests that, in the hands of operators with substantial experience, the heat zone can be shaped and controlled with enough precision to treat tumors even where the margin for error is measured in millimeters. Techniques such as the so-called moving shot method, hydrodissection to push critical structures away from the ablation zone, and continuous monitoring of the patient’s voice during the procedure are among the tools experienced operators use to make this possible.

The authors are careful about what their study can and cannot claim. As a retrospective cohort study, it analyzed archived routine patient data rather than randomly assigning patients to treatment arms, so it cannot rule out selection effects — the possibility that patients chosen for ablation of high-risk tumors differed in subtle ways from those with low-risk tumors. The follow-up of roughly two years on median is also shorter than the slow natural history of papillary thyroid carcinoma would ideally demand; these indolent cancers can recur many years after treatment. And the confidence intervals on the progression analysis, while statistically unremarkable, are wide enough that a modest increase in risk cannot be entirely excluded. The researchers frame their conclusions accordingly: in this retrospective cohort, no statistically significant differences in observed outcomes were detected between the high-risk and low-risk groups, and these preliminary findings support further evaluation of radiofrequency ablation performed by experienced operators in carefully selected patients.

Even with those caveats, the study lands at a consequential moment. The 2024 expert consensus has already shifted the regulatory and clinical landscape toward broader use of thermal ablation, and active surveillance — the watch-and-wait strategy pioneered for small papillary thyroid carcinomas in Japan — has established that many of these tumors can be safely observed without any intervention at all. The emerging picture is one of expanding options rather than a single replacement for surgery: observation for patients comfortable with surveillance, ablation for those who want the tumor treated but dread losing the gland, and surgery for cases where nodal disease or tumor behavior demands it. What the Zhejiang data add is evidence that the anatomical map of the thyroid, long used to draw a bright line between ablatable and non-ablatable tumors, may matter less than the skill of the operator holding the electrode. If larger, prospective studies confirm these results, the treatment of the smallest thyroid cancers may become less about where the tumor sits and more about who is treating it — a shift that could spare thousands of patients a scar, a hospital stay, and a lifetime of daily medication.

Subject of Research: Radiofrequency ablation of T1aN0M0 papillary thyroid carcinoma in high-risk anatomical locations

Article Title: Efficacy and safety of radiofrequency ablation for high-risk locations of T1aN0M0 papillary thyroid carcinoma: a retrospective cohort study

Article References: Wan, F., Xu, L., Lou, H., Shou, J., Xu, H., Li, Q., Zhou, L., Fan, G., & Li, S. (2026). Efficacy and safety of radiofrequency ablation for high-risk locations of T1aN0M0 papillary thyroid carcinoma: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-17125-5

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17125-5

Keywords: papillary thyroid carcinoma, radiofrequency ablation, thyroid cancer, interventional radiology, high-risk location, thermal ablation, active surveillance, recurrent laryngeal nerve, T1aN0M0, retrospective cohort study, minimally invasive therapy, Zhejiang University

The research, published in CVIR Oncology by a team led by Maria Tækker of Aarhus University Hospital, examined percutaneous cryoablation, a technique in which thin, needle-like probes are inserted through the skin directly into a tumor under computed tomography guidance. Once the probes are in position, pressurized argon gas is circulated through their tips, dropping the temperature at the tumor to at least minus 40 degrees Celsius. At that extreme cold, ice crystals form inside and around cancer cells, rupturing membranes and cutting off the blood supply, ultimately killing the tissue through a process of controlled necrosis. Because the expanding ice ball is visible on CT scans as it grows, the radiologist can watch the frozen zone engulf the tumor in real time, ensuring the lethal cold extends at least five millimeters beyond the tumor’s edge while sparing nearby healthy structures.

This real-time visibility is one of cryoablation’s most significant advantages over competing ablative technologies, and it carries a second benefit that is easy to overlook: the procedure can be repeated. Unlike stereotactic body radiation therapy, where cumulative radiation dose limits how many times a region can be treated, or surgery, where each operation adds scar tissue and risk, cryoablation leaves tissue in a state that can safely tolerate another freeze cycle if a tumor returns. For patients with oligometastatic disease, the intermediate state between localized and widespread cancer in which only a limited number of metastases exist in a few organ sites, that repeatability could prove decisive.

The Danish team set out to test exactly that proposition in a group of patients who had run out of conventional options. Between December 2016 and February 2022, sixteen patients with fewer than three histologically verified metastases each were selected for treatment at a single center. Crucially, every case was reviewed by a multidisciplinary team of oncologists, surgeons, pathologists, and radiologists, and all of the patients had already completed treatment for their primary cancers. Many carried significant comorbidities: the most common were hypertension and diabetes, and the average score on the American Society of Anesthesiologists physical status scale, which grades surgical risk, was 2.6, indicating severe systemic disease in several participants. These were not healthy patients; they were people whose age or health made surgery, additional radiation, or more chemotherapy too dangerous, leaving cryoablation as the only feasible curative-intent option.

The technical execution of the procedures reflects the maturity the field has reached. A senior radiologist with a decade of experience in CT-guided interventions performed the ablations, most of them, 73.7 percent, under conscious sedation rather than general anesthesia. Using an argon-based cryoablation system with sealed 14- or 17-gauge cryoprobes, the team created ice balls that covered each tumor with a margin of at least five millimeters. Standard treatments used a double freeze-thaw cycle of ten minutes of freezing followed by eight minutes of thawing, a rhythm that exploits the way repeated freezing damages cells more thoroughly than a single cycle. Lymph node metastases received a triple freeze-thaw protocol, and when tumors sat close to vulnerable structures, the team used hydrodisplacement, injecting fluid to physically push organs such as the bowel away from the freezing zone.

The results, drawn from fifteen patients and sixteen metastases with complete follow-up, are striking for a cohort this fragile. The median tumor size was 18 millimeters, though lesions ranged from 6 to 60 millimeters, and the primary cancers originated in the kidney, lung, and breast. After a single cryoablation treatment, 80 percent of patients achieved local tumor control at a median follow-up of 23.6 months. Three patients whose tumors progressed underwent repeat ablations, and after these retreatments the so-called secondary efficacy rate rose to 93 percent at a median follow-up of 28.7 months. In other words, even when the first freeze failed to eradicate a lesion permanently, freezing it again usually finished the job, validating the technique’s key selling point of repeatability.

The safety profile was equally encouraging. Ninety percent of patients went home the same day. Of the nineteen treatments performed, only two produced post-procedural complications, and just one patient needed overnight hospitalization for monitoring. Graded on the Common Terminology Criteria for Adverse Events scale, complications were limited to grade 1 in 16 percent of procedures and grade 2 in 5 percent, with nothing more severe, and no complication required further intervention. For a population of comorbid patients with stage IV cancer, avoiding the morbidity of surgery or the accumulating toxicity of repeat radiation while still achieving local tumor control represents a genuine clinical gain.

Survival figures rounded out the picture. At one year, 93 percent of patients were alive; at two years, 72 percent; and at three years, 63 percent. The deaths that occurred were attributed to progression of the primary cancers rather than to the procedure itself. These numbers sit comfortably within the range reported by comparable studies, which have shown two-year overall survival of 82 to 94 percent and three-year survival of roughly 62 to 82 percent for metastasis-directed cryoablation. A recent retrospective analysis of 511 patients with lung metastases by Gits and colleagues found no significant survival differences between sublobar resection, stereotactic body radiation therapy, and percutaneous ablation, suggesting that needle-based approaches can stand alongside established local therapies. Meanwhile, literature on radiation-directed treatment of oligometastases indicates that such metastasis-directed therapy may extend expected survival by up to fifteen months, underscoring the stakes of getting local control right.

The study’s authors are candid about its limits. With only fifteen analyzed patients, a retrospective design, and a single center, the findings cannot be generalized blindly, and the inclusion of patients with advanced cancer and high anesthetic risk scores may actually understate the survival that healthier candidates could expect. Tumor size also emerged as a question mark: prior research suggests lesions larger than 20 millimeters carry a higher risk of local progression after cryoablation, and while this study’s tumors ranged well beyond that threshold, the sample was too small to settle the matter. What the data do support is a consistent pattern across diverse anatomical sites, from kidneys and adrenal glands to retroperitoneal soft tissue, lymph nodes, and even the iliac bone, that percutaneous cryoablation is an effective and repeatable method for managing limited metastatic disease over at least a two-year horizon.

The broader significance of the work lies in what it offers patients who have been told their options are exhausted. For someone with two or three metastases and a heart too weak for surgery, a same-day procedure that freezes their tumors under light sedation, with a 93 percent chance of lasting local control after retreatment and no serious complications, changes the calculus of stage IV cancer. The researchers argue that future clinical trials should evaluate overall survival together with quality of life, since both metrics capture what matters most when life is extended at advanced disease stages. High-level randomized evidence comparing cryoablation directly with radiation therapy for oligometastatic disease is still missing, but studies like this one, built on careful multidisciplinary selection, standardized reporting, and honest accounting of failures, are laying the groundwork. For now, the message is simple and quietly revolutionary: sometimes the best answer to a spreading cancer is not more drugs or bigger operations, but a precisely guided blast of cold, delivered through a needle, and repeated as often as needed.

Subject of Research: Percutaneous cryoablation as metastasis-directed therapy for oligometastatic cancer

Article Title: Percutaneous imaging-guided cryoablation of oligometastases – a single-center experience

Article References: Tækker, M., Pietersen, P. I., Junker, T., Jensen, C. G., Vogsen, M., Rasmussen, B. S., Welch, B. T., Persson, G. F., Al-Mashhadi, R., & Graumann, O. (2025). Percutaneous imaging-guided cryoablation of oligometastases – a single-center experience. CVIR Oncology, 1(1), Article 11. https://doi.org/10.1007/s44343-025-00011-5

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00011-5

Keywords: cryoablation, oligometastatic disease, metastases, interventional radiology, CT guidance, cancer treatment, local tumor control, overall survival, minimally invasive therapy, kidney cancer, lung cancer, breast cancer

The study, conducted by Laureen Fröhlich and Andreas H. Mahnken at Marburg University, distributed an anonymous 47-item online questionnaire to 300 fifth-year medical students taking regular radiology courses across two academic terms, between winter 2023 and summer 2024. Eighty-five students completed the survey, a response rate of 28.3 percent, with 67 percent female participants and a mean age of 24.9 years. The questionnaire, based on previously published survey instruments, covered demographic data, students’ knowledge of interventional radiology compared with other disciplines, their familiarity with specific procedures including oncologic, vascular and non-vascular interventions, and their understanding of the specialty’s clinical role. Students completed the survey without any prior teaching intervention, providing a genuine baseline of what five years of medical school had taught them. The study was approved by the institutional ethics committee.

The headline finding is a paradox of awareness without understanding. Every single participant, 100 percent, knew that interventional radiology exists alongside diagnostic radiology. But only 36.5 percent had any prior exposure to the field during their studies, and 67.1 percent rated their own knowledge of it as poor. Not a single student rated their knowledge as excellent, and only 4.7 percent considered it good. The gap between perceived and actual understanding was particularly revealing: 63.5 percent of students claimed to know which diseases interventional radiology could treat, and 58.8 percent said they were aware of the available procedures, yet when tested objectively on specific interventions, their performance collapsed. Only about a third, 35.7 percent, felt they knew when a patient should even be referred to the specialty.

The procedural knowledge test laid bare the blind spot. Students were presented with twelve exemplary interventional radiology procedures and correctly assigned only seven of them to the field. Vascular interventions fared well: 96.5 percent correctly identified arterial revascularization as an interventional radiology procedure, followed by percutaneous angioplasty at 92.9 percent, endovascular aortic repair at 88.2 percent, treatment of arterial bleeding at 84.5 percent and inferior vena cava filter implantation at 76.2 percent. But the oncologic procedures, the very heart of interventional oncology, were recognized far less often. Venous access port implantation for chemotherapy was correctly assigned by only 54.1 percent of students and hepatic artery infusion chemotherapy by 50.6 percent. Fewer than half correctly identified thermal ablation of renal tumors at 48.8 percent, hepatic tumor ablation at 43.5 percent or image-guided lung biopsy at 42.4 percent. Non-vascular procedures fared worst of all, with vertebroplasty recognized by a mere 20 percent of respondents.

The confusion extended beyond ignorance to outright misattribution. Of the five non-interventional-radiology procedures included as distractors, the majority of students failed to correctly exclude any of them. Removal of adrenal tumors and radiation therapy for bone metastases were correctly recognized as outside the field by only 45.8 percent and 42.4 percent of students respectively, while local treatment of rheumatoid arthritis and proton therapy for pancreatic tumors were correctly flagged by just 37.6 percent and 35.3 percent. In other words, many future physicians cannot reliably distinguish what interventional radiologists do from what surgeons, radiation oncologists or nuclear medicine specialists do, a deficit with real clinical consequences, since referring physicians who misunderstand a specialty’s therapeutic potential may delay or miss referrals and exclude minimally invasive, organ-sparing options from multidisciplinary treatment planning.

Students’ picture of the specialty’s clinical structure was similarly incomplete. On the positive side, 97.6 percent recognized that interventional radiology treats patients with serious illnesses, and around 96 percent acknowledged that it performs potentially life-saving interventions. But when asked about the organizational reality of modern practice, understanding wavered: 69 percent assumed interventional radiology departments run their own outpatient clinics, 65.5 percent believed they admit patients independently, and 64.3 percent thought they conduct ward rounds, while only 41.7 percent knew such departments may have their own inpatient beds. These structures are increasingly common as the specialty evolves from a procedural referral service into a fully clinical discipline responsible for the entire patient pathway, from initial consultation through admission, inpatient care, discharge and follow-up.

The career implications may be the most consequential finding of all. Although 70.6 percent of students expressed interest in interventional radiology, and 61.2 percent wanted to learn more about it, radiology as a career was decisively rejected. Not one student said they would definitely consider it, only 5.9 percent said rather yes, and 78.8 percent ruled it out as rather not or definitely not an option. The most cited reason, given by 57.6 percent, was too little patient contact, followed by too much work on the computer at 51.8 percent and simple lack of interest at 50.6 percent. The authors note that this perception of radiologists as isolated, screen-bound technicians is a widespread stereotype, reinforced by low exposure during training and by the shortage of interventional radiology-managed inpatient beds that limits bedside teaching. A European survey by the Cardiovascular and Interventional Radiological Society of Europe’s Trainee Forum found the same trend, with limited patient interaction the most cited deterrent.

This recruitment crisis arrives at precisely the wrong moment. Cancer remains one of the foremost causes of death worldwide, with 19.3 million new cases and nearly 10 million cancer-related deaths in 2020, and the global burden is projected to rise by 47 percent to approximately 28.4 million new cases annually by 2040. Meanwhile, a shortfall of around 10 million healthcare workers is anticipated by 2030, and shortages of clinical radiologists and interventional radiology specialists, worsened by aging, retirement and burnout, are particularly alarming because these specialties are critical for cancer diagnosis, staging and minimally invasive treatment. Crucially, unlike vascular interventions, which are often performed by other disciplines, interventional oncology procedures are carried out exclusively by interventional radiologists, meaning a shortage of incoming talent could directly limit the quality and accessibility of minimally invasive cancer therapy for years to come.

Part of the problem is structural. In the United States, interventional radiology has been recognized as a primary medical specialty since 2012, and the Integrated Interventional Radiology Residency introduced in 2016 established a structured six-year training pathway reflecting the discipline’s full clinical scope. In Europe, no standardized framework exists: in most countries, including Germany, interventional radiology holds no official subspecialty status and is instead embedded within radiology. It is entirely absent from Germany’s official national undergraduate medical curriculum. CIRSE has developed curricula, including an Interventional Radiology Curriculum for Medical Students that treats interventional oncology as a core area, but implementation of these non-mandatory frameworks remains inconsistent and dependent on local initiative. The result, the authors argue, is a self-perpetuating cycle in which invisibility in the curriculum breeds ignorance among students, ignorance deters career interest, and dwindling recruitment deepens the workforce shortage that keeps the specialty too stretched to teach.

Breaking that cycle, the researchers conclude, requires action on several fronts: establishing formal structural recognition of interventional radiology as a specialty or subspecialty, integrating it and interventional oncology into mandatory undergraduate modules, expanding teaching formats from lectures and symposia to bedside teaching and interdisciplinary case discussions, actively promoting the field as the clinical, patient-facing discipline it has become, and harmonizing training standards across Europe. The evidence suggests even modest interventions work, as short lectures and targeted teaching have been shown to improve student knowledge and career consideration. The authors acknowledge limitations, including the single-institution design, the 28.3 percent response rate that may have attracted students already interested in the field, and the use of predefined answer options that may have shaped responses about career objections. Still, the message is difficult to ignore: a field capable of burning away tumors through a pinhole cannot afford to remain, in the minds of the physicians who will soon refer patients to it, out of sight and out of mind.

Subject of Research: Medical students' knowledge and awareness of interventional oncology and interventional radiology in undergraduate medical education

Article Title: Out of sight, out of mind: interventional oncology’s underrepresentation in undergraduate medical education

Article References: Fröhlich, L., & Mahnken, A. H. (2025). Out of sight, out of mind: interventional oncology’s underrepresentation in undergraduate medical education. CVIR Oncology, 1(1), Article 23. https://doi.org/10.1007/s44343-025-00020-4

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00020-4

Keywords: interventional radiology, interventional oncology, medical education, undergraduate curriculum, cancer treatment, tumor ablation, medical students, workforce shortage, radiology career, Germany, survey study, minimally invasive therapy

The study, published in CVIR Oncology as an open-access short communication, enrolled 97 patients with primary or secondary liver malignancies, of whom 74 completed the final analysis. All participants were treated under conscious sedation with analgesia rather than general anesthesia, and all were interviewed systematically about their pain experience at three distinct time points: during catheter placement under CT fluoroscopy, at the time of radiation delivery when the catheters were removed, and later the same evening on the ward. Pain was scored on the standard numeric rating scale from zero, meaning no pain, to ten, meaning maximum pain. The researchers also tracked age, sex, the number of lesions and catheters, prior treatments, tumor volume, tumor location, and complications classified according to Society of Interventional Radiology guidelines.

The technical choreography of the procedure helps explain why the anesthesia question matters so much. Unlike thermal ablation, where a probe is inserted and the tumor is burned or frozen in a single session, CT-guided HDR brachytherapy unfolds in two stages separated by a change of location. First, under CT fluoroscopic guidance, the interventionalist percutaneously places brachytherapy applicators into and around the tumor while the patient receives intravenous midazolam and fentanyl alongside local lidocaine anesthesia at the puncture site. A second physician stands by throughout, monitoring vital signs and titrating medication. Once the catheters are positioned and the planning scan is complete, the puncture sites are sterilely covered and the patient is escorted to a dedicated radiation operating room, where the iridium-192 source delivers its dose. Only after irradiation are the catheters removed, creating a second moment of potential discomfort, and the patient is then observed for roughly an hour before transfer to the regular ward.

The pain data that emerged were strikingly reassuring. At catheter placement, the moment many clinicians would expect to hurt most, 74.5 percent of patients rated their pain as low, in the zero-to-two range, while 19.0 percent reported moderate pain and only 6.5 percent severe pain. At the time of radiation and catheter removal, the picture improved further: 84.0 percent reported low pain, 11.0 percent moderate, and 5.5 percent severe. On the ward afterward, 79.5 percent reported low pain, 16.0 percent moderate, and 4.0 percent severe. The median doses of sedation were modest, 112.5 micrograms of fentanyl and 2 milligrams of midazolam, underscoring how little pharmacological support the procedure actually demands when performed with careful local anesthesia and image guidance.

Two patterns within the data carry practical weight for clinicians. Women reported significantly higher pain at the time of irradiation, with a p-value below 0.001, and the number of treated lesions was associated with significantly higher pain levels at two of the three measured time points, with p below 0.05. No other parameter, including age, tumor volume, tumor location, or the number of prior treatments, showed a significant relationship with pain perception. The authors suggest that these findings point to patient groups, women and those with multiple lesions, who may warrant heightened attention and more aggressive pain management during brachytherapy, rather than a wholesale change in the sedation strategy.

Safety outcomes were equally encouraging. Across three months of follow-up, mild to moderate complications occurred in 23.0 percent of patients, consisting mainly of pain and fever, while no major complications were observed at all. Patient satisfaction, measured on a ten-point scale from complete dissatisfaction to complete satisfaction, was overwhelmingly positive: 98.5 percent of patients scored their experience at seven or higher, and only a single patient recorded the lowest possible score. For a procedure involving the percutaneous puncture of the liver, the placement of multiple catheters, and the delivery of a high radiation dose directly into malignant tissue, a zero rate of major complications in 74 patients is a result that demands attention.

The biological logic of the technique may partly explain why patients tolerate it so well. Unlike radiofrequency or microwave ablation, where heat generation within the liver can be genuinely painful and respiratory movement during the procedure can compromise both safety and effectiveness, the radiation delivered by an HDR iridium-192 source is itself painless. This, the authors note, potentially accounts for the absence of any significant association between tumor location and pain perception in their data. The trade-off is time and logistics: the procedure takes longer than thermal ablation because of the transfer to the radiation room and the delayed catheter removal, and it is precisely this duration and change of setting that makes conscious sedation arguably more practicable than general anesthesia, avoiding the overhead, risks, and resource demands of an anesthesiology team.

The broader context makes the finding timely. Minimally invasive tumor ablation has surged to an all-time high, driven in part by landmark randomized evidence that thermal ablation can match surgical resection for small colorectal liver metastases, and by emerging navigation techniques such as stereotactic puncture that are expanding what image-guided interventions can achieve. Previous work has shown that HDR brachytherapy achieves high rates of local tumor control without strict limitations on tumor size or location, including ablation of large and very large hepatocellular tumors and of lesions with portal vein tumor thrombosis. As the technique moves toward broader adoption, the anesthesia protocol becomes a genuine bottleneck or enabler: if every case requires general anesthesia, throughput is limited and costs rise, whereas a protocol that keeps the patient comfortable while awake can be integrated directly into the clinical routine of an interventional radiology unit.

The study’s authors are candid about its limitations. It was a single-center, monocentric investigation without a comparative arm, and it relied on patient interviews and structured questionnaires, which introduces the possibility of recall bias, since patient-reported data may be influenced by the timing of assessment. The absence of a general anesthesia comparison group means the study cannot definitively settle the ongoing global debate about the optimal anesthesia method for liver ablation, a debate that until now has drawn almost exclusively on hyperthermal ablation procedures rather than brachytherapy. Some studies have even suggested that general anesthesia might offer oncological advantages, although the authors argue that factors such as tumor location and size likely play a more significant role in outcomes than the sedation technique itself.

Even with those caveats, the conclusion is clear and consequential: CT-guided HDR brachytherapy under conscious sedation with analgesia, performed by interventional radiologists themselves, is safe, feasible, and well tolerated, with low subjective pain, near-universal patient satisfaction, and no major complications. Beyond the immediate clinical benefit for patients with liver malignancies, the finding carries a professional significance for the field. Delivering conscious sedation within the interventional radiology unit, without dependence on anesthesiology services, strengthens the specialty’s autonomy and supports its development as an independent clinical discipline. As the number of minimally invasive tumor ablations continues to climb across centers worldwide, this study suggests that the future of precision liver cancer radiation may be one in which patients remain awake, comfortable, and cared for by the same team that guides the catheters, plans the dose, and delivers the cure.

Subject of Research: Feasibility and safety of CT-guided high-dose-rate brachytherapy for liver tumors under conscious sedation with analgesia

Article Title: Feasibility and safety of CT guided high dose rate brachytherapy of liver tumors performed under conscious sedation with analgesia

Article References: Auer, T. A., Erforth, M. Z., Segger, L., Savic, L. J., Fleckenstein, F., Collettini, F., Fehrenbach, U., & Gebauer, B. (2025). Feasibility and safety of CT guided high dose rate brachytherapy of liver tumors performed under conscious sedation with analgesia. CVIR Oncology, 1(1), Article 26. https://doi.org/10.1007/s44343-025-00026-y

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00026-y

Keywords: brachytherapy, liver cancer, interventional radiology, conscious sedation, CT guidance, hepatocellular carcinoma, iridium-192, pain management, tumor ablation, radiation oncology, patient safety, minimally invasive therapy